lipid MANAGEMENT
Elevated LDL-C Can Lead to Cardiovascular Disease (CVD), Which is the Number One Cause of Death1,2
According to American Heart Association estimates, in the US1:
1 in 3
deaths
  • CVD accounts for
    1 in 3 deaths
40
seconds
  • Someone has a heart
    attack approximately
    every 40 seconds
$ 351.2
billion in 2014-15
  • CVD expenses, including stroke, were $351.2 billion in 2014-2015, including the cost of
    healthcare services, medications, and lost productivity
The CDC (Centers for Disease Control), through NHANES (National Health and Nutrition Examination
Survey), estimates that 62.6 million US adults have elevated levels of LDL-C (also known as
hypercholesterolemia) and are eligible to use statins.3*

In the US, increasing attention has been placed on aggressive LDL-C reduction. This has led to the use of a combination of a statin with additional non-statin therapies.4

LDL-C=low-density lipoprotein cholesterol.

Current Treatment Options May Not Be Adequate for All Patients
Existing lipid-lowering statins are effective at lowering LDL-C, leading to well-documented benefits.4
However, not all patients can tolerate statins or reach their LDL-C target on maximally-tolerated
statin-dosing.5-7
~27.4
million
US adults
  • Approximately 27.4 million US adults with elevated LDL-C levels are taking a statin3
~19.4
million
adults
  • Approximately 19.4 million patients with elevated LDL-C levels are currently unable to achieve their LDL-C target despite taking statin therapy3
Patients with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial
hypercholesterolemia (HeFH) who require additional LDL-C lowering on top of maximally-tolerated
statin therapy represent a high-risk patient population with an unmet medical need.3,8

*Statin eligibility is one of the following (not mutually exclusive): ASCVD; LDL-C≥190 mg/dL; 40-75 y.o. with diabetes, LDL-C 70-189 mg/dL, without ASCVD; 40-75 y.o. without ASCVD or diabetes, with LDL-C 70-189 mg/dL and ≥7.5%
10-year ASCVD risk.

Learn how our agents may change the current paradigm.
References: 1. Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke
statistics—2019 update: a report from the American Heart Association. Circulation. 2019;139:00–00. doi:10.1161/CIR.0000000000000659. 2. World Health Organization. Cardiovascular diseases (CVDs).
https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). Accessed February 15,
2019.
3. Wong ND, Young D, Zhao Y, et al. Prevalence of the American College of
Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein
cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011–2012. J Clin Lipidology. 2016;10:1109-1118. 4. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on
Clinical Practice Guidelines. Circulation. 2018. Nov 10:CIR0000000000000624. doi:10.1161/CIR.0000000000000624. 5. Gibson TB, Mark TL, Axelsen K, Baser O, Rublee DA, McGuigan KA. Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care. 2006;12:SP11-SP19. 6. Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): An internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6:208-215.
7. Raymond C, Cho L, Rocco M, Hazen SL. New guidelines for reduction of blood cholesterol: Was it worth the wait? Cleve Clin J Med. 2014;81(1):11-19. 8. Nordestgaard BG, Chapman MJ, Humphries SE, et
al. for the European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary
heart disease. Eur Heart J. 2013;34:34783490.